Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
|Articles|December 16, 2021
Pharmacy Clinical Pearl of the Day: Genital Herpes
Author(s)Saro Arakelians, PharmD
After the initial infection, herpes virus lies dormant in the body and can reactivate several times a year.
Advertisement
Clinical Pearl of the Day: Genital Herpes
Genital herpes is a common sexually transmitted infection caused by the herpes simplex virus (HSV).
Insight:
- Sexual contact is the primary way that HSV spreads.
- After the initial infection, HSV lies dormant in the body and can reactivate several times a year.
- GSV can cause pain, itching, and sores in the genital area.
- There's no cure for GSV, but medications can ease the symptoms and reduce the risk of infecting others.
- Condoms also can help prevent the spread of a GSV infection.
- Symptoms include pain or itching, small red bumps, or tiny white blisters, ulcers, and scabs.
- Causes may include HSV-1 and HSV-2.
- Risk factors may include being a woman and having multiple partners.
- Treatments include acyclovir (Zovirax) and valacyclovir (Valtrex).
Sources:
Advertisement
Related to this article
Two Kidney Week 2026 abstracts show a dose-response link between cardiovascular-kidney-metabolic syndrome (CKM) stage and chronic kidney disease (CKD), while primary care clinicians cite evidence and workflow barriers.
In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.
Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.
In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.
Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
2
SGLT2 Inhibitors Benefit Frail Adults With T2D, Remain Underused
3
FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D
4
Combined Cardiometabolic Biomarker Burden Tracks CKM Progression
5